Efficacy of cefiderocol against carbapenem-resistant gram-negative bacilli in immunocompetent-rat respiratory tract infection models recreating human plasma pharmacokinetics

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 9, 2017, Pages

  Matsumoto, Shuhei ^a   Singley, Christine M ^b   Hoover, Jennifer ^b   Nakamura, Rio ^a   Echols, Roger ^c   Rittenhouse, Stephen ^b   Tsuji, Masakatsu ^a   Yamano, Yoshinori ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b GLAXOSMITHKLINE   (United States)

^c Infectious Disease Drug Development Consulting LLC   (United States)

Author keywords

Carbapenem resistant; cefiderocol; Rat respiratory tract infection model; Recreating human PK; S 649266

Indexed keywords

ANTIINFECTIVE AGENT; CEFIDEROCOL; CEPHALOSPORIN DERIVATIVE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANIMAL; BETA-LACTAM RESISTANCE; BLOOD; DISEASE MODEL; DRUG EFFECT; GENETICS; KLEBSIELLA INFECTION; KLEBSIELLA PNEUMONIAE; MALE; MICROBIOLOGY; MULTIDRUG RESISTANCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RAT; RESPIRATORY TRACT INFECTION; SPRAGUE DAWLEY RAT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CEPHALOSPORINS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RATS; RATS, SPRAGUE-DAWLEY; RESPIRATORY TRACT INFECTIONS;

EID: 85028329370     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00700-17     Document Type: Article

References (31)

1. Boucher H, Talbot G, Bradley J, Edwards J, Gilbert D, Rice L, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1–12. https://doi.org/10.1086/595011.
2. Kallen A, Hidron A, Patel J, Srinivasan A. 2010. Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006–2008. Infect Control Hosp Epidemiol 31:528–531. https://doi.org/10.1086/652152.
3. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA. https://www.cdc.gov/drugresistance/threat-report-2013/.
4. Centers for Disease Control and Prevention. 2013. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep 62(9):165–170. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6209a3.htm.
5. Falagas ME, Kasiakou SK. 2005. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40:1333–1341. https://doi.org/10.1086/429323.
6. Giamarellou H, Poulakou G. 2009. Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs 69:1879–1901. https://doi.org/10.2165/11315690-000000000-00000.
7. Cai Y, Chai D, Wang R, Liang B, Bai N. 2012. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 67:1607–1615. https://doi.org/10.1093/jac/dks084.
8. Bradford PA, Kazmierczak KM, Biedenbach DJ, Wise MG, Hackel M, Sahm DF. 2015. Correlation of -lactamase production and colistin resistance among Enterobacteriaceae isolates from a global surveillance program. Antimicrob Agents Chemother 60:1385–1392. https://doi.org/10.1128/AAC.01870-15.
9. van Duin D, Kaye KS, Neuner EA, Bonomo RA. 2013. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis 75:115–120. https://doi.org/10.1016/j.diagmicrobio.2012.11.009.
10. Kumar M. 2016. Colistin and tigecycline resistance in carbapenem-resistant Enterobacteriaceae: checkmate to our last line of defense. Infect Control Hosp Epidemiol 37:624–625. https://doi.org/10.1017/ice.2016.31.
11. Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, Rhomberg PR, Jones RN, Yoshizawa H, Nakamura R, Tsuji M, Yamano Y. 2016. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. J Antimicrob Chemother 71:670–677. https://doi.org/10.1093/jac/dkv402.
12. Kohira N, West J, Ito A, Ito-Horiyama T, Nakamura R, Sato T, Rittenhouse S, Tsuji M, Yamano Y. 2016. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother 60:729–734. https://doi.org/10.1128/AAC.01695-15.
13. Ito A, Nishikawa T, Matsumoto S, Yoshizawa H, Sato T, Nakamura R, Tsuji M, Yamano Y. 2016. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother 60:7396–7401. https://doi.org/10.1128/AAC.01405-16.
14. Ito-Horiyama T, Ishii Y, Ito A, Sato T, Nakamura R, Fukuhara N, Tsuji M, Yamano Y, Yamaguchi K, Tateda K. 2016. Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob Agents Chemother 60:4384 – 4386. https://doi.org/10.1128/AAC.03098-15.
15. Hackel M, Tsuji M, Echols R, Sahm D. 2016. In vitro antibacterial activity of cefiderocol (S-649266) against Gram-negative clinical strains collected in North America and Europe (SIDERO-WT-2014 study). IDWeek 2016, poster 1828.
16. Nakamura R, Toba S, Ito A, Tsuji M, Yamano Y, Shimada J. 2014. S-649266, a novel siderophore cephalosporin. V. Pharmacodynamic assessment in murine thigh infection models. 54th Intersci Conf Antimicrob Agents Chemother, poster F-1559.
17. Osthoff M, Siegemund M, Balestra G, Abdul-Aziz MH, Roberts JA. 2016. Prolonged administration of -lactam antibiotics—a comprehensive review and critical appraisal. Swiss Med Wkly 146:w14368. https://doi.org/10.4414/smw.2016.14368.
18. Berry V, Hoover J, Singley C, Woodnutt G. 2005. Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae. Antimicrob Agents Chemother 49:908–915. https://doi.org/10.1128/AAC.49.3.908-915.2005.
19. Woodnutt G, Berry V. 1999. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 43:29–34.
20. Woodnutt G, Berry V. 1999. Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 43:35–40.
21. Hoover JL, Lewandowski TF, Mininger CL, Singley CM, Sucoloski S, Rittenhouse S. 2017. A robust pneumonia model in immunocompetent rodents to evaluate antibacterial efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii. J Vis Exp 2017(119):55068. https://doi.org/10.3791/55068.
22. Singley C, Page R, Hoover J, Elefante P, DeMarsh P. 2011. Efficacy of a LeuRS inhibitor GSK2251052 against Pseudomonas aeruginosa using a computer-controlled infusion system to recreate human exposure profiles in rats. 51st Intersci Conf Antimicrob Agents Chemother, poster F2-1866.
23. Singley C, Page R, Hoover J, Elefante P, DeMarsh P. 2011. Efficacy of a LeuRS inhibitor GSK2251052 against Enterobacteriaceae isolates using a computer-controlled infusion system to recreate human PK profiles in rats. 21st Eur Cong Clin Microbiol Infect Dis, poster 1508.
24. Clinical and Laboratory Standards Institute. 2016. Performance standards for antimicrobial susceptibility testing; twenty-seventh edition. CLSI document M100-S27. Clinical and Laboratory Standards Institute, Wayne, PA.
25. Endimiani A, Hujer AM, Perez F, Bethel CR, Hujer KM, Kroeger J, Oethinger M, Paterson DL, Adams MD, Jacobs MR, Diekema DJ, Hall GS, Jenkins SG, Rice LB, Tenover FC, Bonomo RA. 2009. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother 63:427–437. https://doi.org/10.1093/jac/dkn547.
26. Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard—tenth edition. CLSI document M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA.
27. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
28. Smith G. 1991. A simple non-surgical method of intrabronchial instillation for the establishment of respiratory infections in the rat. Lab Anim 25:46–49. https://doi.org/10.1258/002367791780808130.
29. Katsube T, Echols R, Arjona FJ, Krenz H, Berg J, Galloway C. 2017. Cefiderocol, a siderophore cephalosporin for Gram-negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment. J Clin Pharmacol 57:584–591. https://doi.org/10.1002/jcph.841.
30. Shimada J, Saisho Y, Katsube T, White S, Fukase H. 2014. S-649266, a novel siderophore cephalosporin for Gram negative bacterial infections: pharmacokinetics (PK), safety and tolerability in healthy subjects. 54th Intersci Conf Antimicrob Agents Chemother, poster F-1564.
31. Okumura K, Tsuji H, Takeda K, Fukuda I, Nagaki T, Takano M, Higo K, Kinami J. 1983. Absorption, distribution, metabolism and excretion of ceftazidime in mice, rats and rabbits. Chemotherapy 31(Suppl 3): 188–198.